T-Cell Redirection Therapy Studied for Relapsed Multiple Myeloma

THURSDAY, Sept. 15, 2022 -- In patients with heavily pretreated relapsed/refractory multiple myeloma with relapse after bispecific antibody (BiAb) T-cell redirection therapy, subsequent T-cell redirection therapy is feasible as salvage therapy,...